Skip to main content

Advertisement

Table 3 Changes of disease activities and medications

From: Effects of denosumab on bone mineral density and bone turnover markers in rheumatoid arthritis patients switching from bisphosphonates

  Naïve group (n = 25) Switch group (n = 11)
Variable Baseline 6 months 12 months Baseline 6 months 12 months
DAS28-ESR 3.60 ± 0.17 3.55 ± 0.14 3.57 ± 0.16 4.15 ± 0.32 4.07 ± 0.32 3.93 ± 0.30
SDAI 6.90 ± 1.00 7.34 ± 0.99 7.36 ± 0.99 9.93 ± 1.38 10.1 ± 2.00 9.52 ± 2.09
MTX (%) 60.0 60.0 60.0 45.5 45.5 45.5
MTX dose (mg/week) 8.1 ± 0.9 7.9 ± 1.0 7.7 ± 1.0 7.2 ± 1.4 7.2 ± 1.4 7.2 ± 1.4
PSL (%) 32.0 28.0 32.0 54.5 54.5 63.6
PSL dose (mg/day) 5.3 ± 1.4 4.7 ± 1.0 4.0 ± 0.9 3.2 ± 0.6 3.2 ± 0.6 3.4 ± 0.6
bDMARDs (%) 32.0 32.0 32.0 54.5 54.5 54.5
csDMARDs (%) 36.0 40.0 40.0 27.3 27.3 27.3
  1. Data are presented as means ± standard deviation (SD), Naïve group: treatment-naïve group; Switch group: transitioning from bisphosphonate group; DAS: disease activity score; SDAI: simplified disease activity score; MTX: methotrexate; PSL: prednisolone; bDMARDs: biological disease-modifying anti-rheumatic drugs; csDMARDs: conventional synthetic disease-modifying anti-rheumatic drugs (salazosulfapyridine, iguratimod, bucillamine, tacrolimus); P values from Wilcoxon’s rank sum test for continuous variables and McNemar’s test for dichotomous variables for the change from baseline within each treatment group. There was no significant change from baseline in all parameters